LRRIQ3 and major depressive disorder: The published studies (Johnston et al., 2019; Sanchez-Roige et al., 2021) that associated LRRIQ3 with major depressive disorder and opioid usage acknowledged the overlapping promoter of this gene, albeit in the opposite direction, with a run-through transcript of FPGT-TNNI3K – previously shown to be associated with BMI in European Graff et al., 2013 and Korean populations (Lee et al., 2017).